Hyperfibrinogenemia alone does not affect the patency of microvascular anastomosis: clinical experience and animal study.
Preventing vascular thrombosis in microsurgery is a prerequisite for a successful outcome. High plasma fibrinogen levels have been associated with thromboembolic risk in patients with cancer or cardiovascular disease. Patients with these comorbidities and associated hyperfibrinogenemia oftentimes require microsurgical reconstruction. This situation causes us to hesitate. Previously in our experience, 8 of 10 patients with hyperfibrinogenemia (> 500 mg/dL) underwent successful free-tissue transfer after oral cancer ablation. Based on this clinical observation, we investigated whether hyperfibrinogenemia contributes to the patency of a microvascular anastomosis. Optimal dosage of fibrinogen (300 mg/kg, intravenously) significantly increased the fibrinogen level in the plasma of the rodent hyperfibrinogenemia model. Forty male Lewis rats (weight = 300-350 g) were injected intravenously by normal saline and fibrinogen (300 mg/kg), respectively (n = 20 in each subgroup). Femoral artery and femoral vein division and reanastomosis were performed after 2 hours in rats with or without fibrinogen injection. The platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT), and the platelet aggregation test induced with adenosine diphosphate (ADP) were also measured preoperatively. The ratios of circulating activated platelets as demonstrated by p-selectin (CD62P) was analyzed by flow cytometry preoperatively and 2 hours postoperatively. Laser Doppler flowmetry was used to assess the patency of the anastomosis preoperatively and 2 hours postoperatively. Vascular patency was assessed 7 days postoperatively. The results showed that the platelet count, PT and APTT levels had no significant difference among the control and the experimental group. There were no significant differences found in the ratios of CD62P expression (P = 0.65) and ADP aggregation test (P = 0.17) in comparing both groups. There were no statistical differences in the patency rates (P > 0.05) or perfusion units of femoral arteries (P = 0.84) and femoral veins (P = 0.51) after vessels division and reanastomosis, respectively. In summary, there was no correlation between experimentally induced hyperfibrinogenemia and the enhancement of thrombosis risk after microvascular surgery. This experimental data can lend support to the idea that microvascular anastomosis could be safely performed in patients with hyperfibrinogenemia alone without untoward thrombotic complications.